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Abstract: In this paper, we report the use of lead sulﬁ  de quantum dot (PbS QD) bioconjugates 
as near infrared (NIR) contrast agents for targeted molecular imaging with expanded emission 
wavelengths beyond 1000 nm. The red-shifted emission band, coupled with the small particle 
size, which will facilitate clearance, both afford PbS QDs unique properties for noninvasive, high 
resolution in vivo NIR imaging applications. We have performed imaging experiments at the 
molecular level using surface-modiﬁ  ed PbS NIR QDs, together with our lab-built NIR imaging 
system. This novel instrumentation and ﬂ  uorescent contrast agent have enabled us to study the 
relatively unexplored NIR biomedical imaging spectral region of 900–1200 nm. Preliminary 
experimental results indicate that PbS-QD/antibody bioconjugates are promising candidates for 
targeted NIR molecular imaging and future in vivo NIR tissue imaging applications. 
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Introduction
In this paper, we report the ﬁ  rst attempt to use lead sulﬁ  de (PbS) near-infrared (NIR) 
quantum dot (QD) bioconjugates with imaging wavelengths beyond 1000 nm as 
molecular-speciﬁ  c contrast agents for targeted imaging applications. For example, the 
photoluminescent band of PbS QDs shown in Figure 1 peaks at around 1010 nm in 
phosphate buffered saline (PBS), and their excitation spectrum spans from the UV to 
NIR region (Zhu et al 2007). Before surface modiﬁ  cation, the average size of the PbS 
QDs is ~4–5 nm, with no signiﬁ  cant increase in size observed after surface coating 
of the particles (Zhu et al 2007). The longer emission wavelength, coupled with the 
small particle size, which facilitates clearance (Zimmer et al 2006), both afford PbS 
QDs unique properties for noninvasive, high resolution in vivo NIR imaging applica-
tions (Kim et al 2004; Chang et al 2005; Michalet et al 2005; Cai et al 2006). The 
“therapeutic window” of the NIR spectrum, 700–1200 nm, enables light to penetrate 
several centimeters deep into the tissue, thereby making PbS QDs ideal for in vivo 
deep-tissue imaging and diagnostics (Wilson and Jacques 1990; Weissleder 2001; 
Michalet et al 2005). While numerous groups have reported various ﬂ  uorescent NIR 
imaging contrast agents, most of these agents possess the emission spectral range of 
700–900 nm (Medintz et al 2005; Michalet et al 2005; Cai et al 2006). However, to 
date, the NIR spectral region of 900–1200 nm has not been sufﬁ  ciently investigated 
for biomedical imaging applications, because of the lack of suitable contrast agents, 
as well as imaging systems, etc (Wilson and Jacques 1990; Michalet et al 2005).
To address these issues, the current study demonstrates how we have combined 
novel instrumentation with surface modiﬁ  ed PbS QDs, allowing us to explore the NIR 
spectral region, as noted above. Speciﬁ  cally, we have carried out molecular level imaging 
experiments using our surface-modiﬁ  ed PbS NIR QDs (Zhu et al 2007) together with 
our lab-built NIR imaging system. These experiments, discussed below, were conducted 
with a view toward future in vivo animal screening. To explain, a wide range of visible International Journal of Nanomedicine 2007:2(2) 236
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light (500–700 nm) has been used as excitation for PbS QDs 
imaging. The red-shifted excitation band of the NIR QDs, 
on the other hand, not only provides deeper penetration into 
tissue than the excitation band of visible QDs (Wu et al 2003; 
Kim et al 2004; Michalet et al 2005), but also avoids most of 
the absorption peaks of tissue ﬂ  uorophores that usually give 
strong auto-ﬂ  uorescence backgrounds (Richards-Kortum 
and Sevick-Muraca 1996). Hence, the NIR imaging method 
presented will potentially provide appealing results for both 
in vivo tissue screening and imaging applications.
Compared with traditional organic NIR ﬂ  uorophores, 
the absorption and photoluminescent spectra of semicon-
ductor nanocrystals can be easily tailored by changing the 
size and shape of the particles. This provides ﬂ  exibility in 
many biological and clinical imaging applications (Hines 
and Scholes 2003; Chang et al 2005; Medintz et al 2005; 
Cai et al 2006). Furthermore, both the chemical and physical 
environmental stabilities of quantum dots, as well as their 
high quantum yield efﬁ  ciency, make them highly desirable 
as ﬂ  uorescent imaging contrast agents (Chan and Nie 1998; 
Medintz et al 2005; Michalet et al 2005). PbS QDs used 
in the following work are synthesized (Hines and Scholes 
2003) and surface modiﬁ  ed in accordance with methods 
presented in previous publications (Medintz et al 2005; 
Zhu et al 2007).
Materials and methods 
The development of molecular-speciﬁ  c imaging techniques 
remains of great interest for diagnostic applications (Wu 
et al 2003; Michalet et al 2005). In particular, contrast agents 
that speciﬁ  cally target disease-associated biomarkers provide 
a convenient means for cancer screening and detection at 
the onset of disease, a period of time that is critical for both 
effective diagnosis and treatment (Chan and Nie 1998; Wu 
et al 2003; Loo et al 2005; Michalet et al 2005). Our study 
speciﬁ  cally addresses the expression of human epidermal 
growth factor receptor 2 (HER2), which is over-expressed 
in living human breast carcinoma cells (Wu et al 2003; Loo 
et al 2005). To image the expression of these receptors, two 
kinds of QD/antibody bioconjugates are prepared. Both 
anti-HER2 and anti-immunoglobulin G (anti-IgG) antibod-
ies are conjugated to PbS QDs, as speciﬁ  c and nonspeciﬁ  c 
imaging contrast agents, respectively (Wu et al 2003; Loo 
et al 2005). 
QD/antibody conjugation 
The modiﬁ  ed PbS QDs surfaces are terminated with carboxyl 
groups (Zhu et al 2007), and they are attached to antibodies 
through EDC and Sulfo-NHS cross-linkers (Wu et al 2003; 
Chang et al 2005). Brieﬂ  y, ~0.2 nmol surface-modiﬁ  ed PbS 
QDs suspended in 1x phosphate-buffered saline (PBS) (pH 
7.2) are activated with EDC (1mg) and Sulfo-NHS (1mg) 
(Pierce, Rockford, IL) for 30 min by gentle stirring. Follow-
ing the activation, excess EDC and Sulfo-NHS are removed 
from the reaction with desalt spin columns (Pierce, Rockford, 
IL). The ﬁ  ltered solution is evenly split into two aliquots, 
~0.1 nmol-activated QDs per aliquot. Anti-HER2 (~0.22 
nmol) (Labvision, Fremont, CA) and anti-IgG (~0.22 nmol) 
(Sigma-Aldrich, St. Louis, MO) antibodies are added to 
each aliquot, respectively, and allowed to react for 0.5–1 h, 
with gentle stirring. Polyethylene glycol-amine (PEG-NH2) 
and Tris buffer (pH 7.0) are then added at the end of the 
conjugation to react with excess carboxyl and activated ester 
groups. These QD/antibody conjugates are allowed to react 
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Figure 1 (a) Absorption and photoluminescent spectra of PbS QDs. (b)TEM images of PbS QDs after surface coating with a 10 nm scale bar.   Adapted with permission 
from Zhu M-Q, Chang E, Sun J, et al. 2007. Surface modiﬁ  cation and functionalization of semiconductor quantum dots through reactive coating of silanes in toulene. J Mater 
Chem, 17:800-5 Copyright © 2007.
Abbreviations: PbS, lead sulﬁ  de; QD, quantum dots; TEM, transmission electron microscopy.International Journal of Nanomedicine 2007:2(2) 237
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overnight at 4 °C and then readied for targeted imaging (Wu 
et al 2003; Chang et al 2005; Loo et al 2005).
Cell culture
HER2 over-expressed SK-BR-3 human breast cancer cells 
are cultured in McCoy’s 5A modiﬁ  ed medium (ATCC, 
Manassas, VA) with 10% fetal bovine serum (FBS) (In-
vitrogen, Carlsbad, CA) and 1% antibiotics. Cells are 
allowed to grow on Lab-Tek 4-chambered coverglass 
(Nalge Nunc Inc., Rochester, NY) for 24 h at 37 °C and 5% 
CO2 incubation before targeting. 
QD-bioconjugates targeting of cells
Culture medium from each of the cell chambers is removed, 
and cells are rinsed with PBS (0.6 mL/chamber). 0.3 mL 
paraformaldehyde (3%–4%) in PBS is added to each cham-
ber to ﬁ  x the cells, and this reaction is allowed to stand for 
15 min at room temperature (r.t.) (Wu et al 2003). The ﬁ  xed 
cells are washed 2–3 times with PBS (0.6 mL/chamber) to 
eliminate the inﬂ  uence of the ﬁ  xing solution. Following the 
washing, 2% BSA/PBS solution is added to three chambers, 
with 0.3 mL/chamber, to block the nonspeciﬁ  c binding sites 
on the cell surface (Wu et al 2003). This process takes 10–15 
min at room temperature. After blocking, all 3 chambers of 
the cells are washed with PBS. PbS-QDs/anti-HER2 conju-
gates in PBS 0.4 mL (~50 nM or ~35 nM) are then added 
to one chamber of the blocked cells. Meanwhile, the same 
amount and concentration of PbS-QDs/anti-IgG conjugates 
in PBS are added to another chamber of blocked cells. 0.4 
mL PBS is added to the third chamber as a control sample. 
The targeting process is allowed to react for 3–4 h at r.t. on 
a gently moving orbital shaking plate, avoiding light. All of 
the cells in the three chambers are washed with PBS after the 
targeting process to remove free QD/bioconjugates. These 
QD-targeted cell samples and the control sample are ﬁ  xed 
and washed again. Finally, 0.4 mL PBS is added to each of 
the three chambers to preserve the moisture, and the samples 
are ﬁ  nally ready for imaging.
Cell imaging
QD/bioconjugate-targeted cells and the control sample 
are imaged with a lab-built NIR imaging system which 
consists of a 2D OMA V InGaAs camera attached to an 
Axiovert 200 M inverted microscope. The liquid nitro-
gen-cooled 320 × 256 pixel 2D OMA V InGaAs focal 
plane array detector and the silicon multiplexer readout 
electronics give excellent response in the NIR region 
from 800 to 1700 nm (Princeton-Instruments 2005). 
Filtered light from a mercury arc-discharge lamp is used 
for excitation, with a bandpass range of 500–700 nm. 
An 800 nm longpass filter is used as the emission filter. 
An NIR-optimized dichroic mirror has been chosen to 
work with these filter sets (Chroma, Rockingham, VT). 
Photoluminescent images and their corresponding bright 
field images of the QD/bioconjugate-targeted cells, 
together with the control sample (Figure 2 and 3), are 
Figure 2 Bright ﬁ  eld (a–c) and photoluminescent (d–f) images of SK-BR-3 cells targeted with PbS-QD/anti-HER2 (~50 nM) (a, d) and PbS-QD/anti-IgG (~50 nM) (b, e) 
bioconjugates. SK-BR-3 cells incubated with PBS are used as control (c, f). All images are in the same scale with a 50 μm scale bar (40x).
Abbreviations: IgG, immunoglobulin G; PbS, lead sulﬁ  de; PBS, phosphate-buffered saline; QD, quantum dots.
(a) (b) (c)
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all examined with this imaging system. All of the three 
luminescent images in Figure 2 are taken and processed 
under the same experimental conditions, and the same 
background has been subtracted during image correction 
(Princeton-Instruments 2005). Following the same pro-
cedure, Figure 3 is obtained.
Toxicity of QD-bioconjugates 
to SK-BR-3 cells
The cytotoxicity introduced by our surface-modified 
PbS-QD/antibody conjugates in SK-BR-3 cells was studied 
with a LIVE/DEAD viability assay (Invitrogen). The same 
amount of SK-BR-3 cells are allowed to grow on Lab-Tek 
chambered coverglass (4 chambers) for 46 h at 37 °C and 
5% CO2 incubation and thoroughly rinsed with D-PBS 
(at least 3 times) to eliminate dead cells. The washed cells 
are incubated with testing particles over a period of 4 h at 
37 °C before viability stains are applied. The stained cells 
are examined under ﬂ  uorescence and bright ﬁ  eld microscopy 
with a Zeiss Axiovert 200 M inverted microscope equipped 
with proper ﬁ  lter sets.
Results and discussion
Qualitatively, as shown in Figure 2 (taken with 40x objective) 
and Figure 3 (taken with 20x objective), PbS-QD/anti-HER2-
targeted cells have the brightest luminescent images with the 
best contrast when compared with either cells targeted by 
PbS-QD/anti-IgG conjugates or control cells incubated with 
PBS. These results agree with previous reports (Chan and 
Nie 1998; Wu et al 2003; Loo et al 2005). Since SK-BR-3 
human breast cancer cells are HER2 over-expressed, they 
demonstrate more favorable binding efﬁ  ciency with the anti-
HER2-conjugated QDs than with anti-IgG-conjugated QDs 
(Wu et al 2003; Loo et al 2005). Therefore, the signiﬁ  cantly 
increased luminescent signal and image contrast in the NIR 
range may be particularly ascribed to the PbS QDs labeling of 
the HER2 receptors (Chan and Nie 1998; Wu et al 2003; Loo 
et al 2005). It is worthwhile noting that both the luminescent 
intensities and contrast of PbS-QD/anti-IgG-targeted cells are 
much lower than those of the PbS-QD/anti-HER2-labeled 
cells. These same measurements are, however, still higher 
than those of the control sample, which has no detectable 
luminescent signal in the NIR (>800 nm) region (Figure 2 
Figure 3 Bright ﬁ  eld (a–c) and photoluminescent (d–f) images of SK-BR-3 cells targeted with PbS-QD/anti-HER2 (~35 nM) (a, d) and PbS-QD/anti-IgG (~35 nM) (b, e) 
bioconjugates. SK-BR-3 cells incubated with PBS are used as control (c, f). All images are in the same scale with a 100 μm scale bar (20x).
Abbreviations: IgG, immunoglobulin G; PbS, lead sulﬁ  de; PBS, phosphate-buffered saline; QD, quantum dots.
(a) (c) (b)
(d) (e) (f)International Journal of Nanomedicine 2007:2(2) 239
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Figure 4. LIVE/DEAD test of SK-BR-3 cells incubated with PbS-QD/anti-HER2 bioconjugates. Calcein ﬂ  uorescence (a) and bright ﬁ  eld 
(b) images with a 100 μm scale bar (10x).
Abbreviations: PbS, lead sulﬁ  de; QD, quantum dots.
(a) (b)
and 3). The difference between the QDs/anti-IgG-labeled 
cells and the control cells likely results from the nonspeciﬁ  c 
binding of anti-IgG antibodies to the cell surfaces (Wu et al 
2003; Loo et al 2005). It is also important to consider that 
improved image quality is expected after further optimization 
of the NIR imaging system.  
Aside from the development of effective contrast agents, 
still another important issue for in vivo imaging applications 
of quantum dots derives from their toxicity, which varies with 
different surface coatings (Medintz et al 2005; Delehanty 
et al 2006; Zhu et al 2007). Preliminary results show that, 
within an acute incubation range of 4 h, cells incubated with 
anti-HER2-conjugated PbS QDs (~35 nM) (Figure 4), anti-
IgG-conjugated PbS QDs (~35 nM) and unconjugated PbS 
QDs (~35 nM), respectively, show no signiﬁ  cant statistical 
difference in viability when compared with the control cells 
that are incubated with D-PBS. Notwithstanding these results, 
further tests are in progress to fully assess the toxicity of these 
QD bioconjugates over a longer period of time.
Moreover, the presented technique has unique advantages 
for future in vivo pre-cancer/cancer screening and imaging 
implementations particularly for the large cohort of breast 
cancer patients who are HER2 positive (Ross and Fletcher 
1998; Horton 2001). To explain, both the red-shifted 
excitation and emission bands of these PbS NIR QDs allow 
for deep-tissue diagnosis. The relatively small size of these 
particles is believed to facilitate body clearance which is 
crucial for in vivo implementations (Zimmer et al 2006). 
Additionally, the general tunability of the emission peak 
of these nanoparticles offers ﬂ  exibility in clinical imaging 
applications (Hines and Scholes 2003; Medintz et al 2005; 
Cai et al 2006). Although the relatively high cost of the 
current lab-built NIR imaging system might be one of the 
disadvantages of this technique, the total equipment expenses 
are expected to decrease dramatically with breakthroughs in 
sensor fabrication technologies and system optimization.
Conclusions 
In conclusion, the main objective of this work is to study 
PbS QD bioconjugates with expanded emission wavelengths 
beyond 1000 nm as NIR contrast agents for targeted molecu-
lar imaging. We are able to study the relatively unexplored 
NIR biomedical imaging region of 900–1200 nm with the 
help of PbS QDs and the latest lab-built NIR imaging sys-
tem. The proof-of-concept imaging results and the prelimi-
nary cytotoxicity tests all indicate that PbS-QD/anti-HER2 
bioconjugates are promising candidates for targeted NIR 
molecular imaging with SK-BR-3 breast cancer cells and 
future in vivo NIR tissue imaging applications.
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